Stemline Shares Take Off on $677 Million Buyout Offer by Global Pharmaceutical Firm
Source: Streetwise Reports  (5/4/20)
Shares of Stemline Therapeutics traded 150% higher after the company reported that it has entered into a definitive agreement to be acquired by Italy's Menarini Group in a deal valued at up to $677 million. More >

Seattle Genetics Shares Trade Higher on Q1/20 Earnings and 22% Growth in ADCETRIS Sales
Source: Streetwise Reports  (5/1/20)
Seattle Genetics shares traded 8% higher, reaching a new 52-week high, after the company reported Q1/20 financial results which included a 10% y-o-y increase in net revenues fueled by a 22% increase in sales of ADCETRIS® and a strong debut for PADCEVâ„¢ in its first full quarter of sales. More >

Biotech Cleared for Phase 2b/3 Trial of NMDA Receptor Antagonist for COVID-19 Patients in Canada
Source: Streetwise Reports  (4/30/20)
Algernon Pharmaceuticals reported it received approval from Health Canada for a Phase 2b/3 multinational clinical study of Ifenprodil in COVID-19 patients to prevent progression to intubation and mechanical ventilation. More >

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients
Source: Streetwise Reports  (4/29/20)
Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. More >

Avadel Shares Rise and Shine on Positive Phase 3 Narcolepsy Study Findings
Source: Streetwise Reports  (4/27/20)
Avadel Pharmaceuticals' shares traded 25% higher reaching a new 52-week high price after the company reported positive topline results from its Pivotal Phase 3 REST-ON trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. More >

Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS
Source: Streetwise Reports  (4/24/20)
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. More >

Biopharma Approved to Launch COVID-19 Trial in South Korea
Source: Streetwise Reports  (4/23/20)
Algernon Pharmaceuticals will evaluate one of its drugs in coronavirus-infected patients with severe pneumonia. More >

BARDA Award Provides 'Lift-off for Biotech's COVID Vaccine'
Source: Streetwise Reports  (4/22/20)
The ways in which Moderna is to use the funds are explained and an update on its coronavirus vaccine is provided in a ROTH Capital Partners report. More >

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'
Source: Streetwise Reports  (4/22/20)
The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. More >

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results
Source: Streetwise Reports  (4/20/20)
Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced renal cell carcinoma. More >

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress
Source: Streetwise Reports  (4/15/20)
A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. More >

Lifeway Foods' Shares Rise 40% on Positive Q1 Sales Data with March Revenue Up 13% Y-O-Y
Source: Streetwise Reports  (4/15/20)
Shares of Lifeway Foods traded higher as the company reported it has increased production to support accelerated demand during the COVID-19 health crisis. More >

MEI Pharma Shares Rise 50% on $682.5M Partnership with Japanese Company to Treat B-cell Malignancies
Source: Streetwise Reports  (4/14/20)
Shares of MEI Pharma traded higher after the company announced that it has entered into development and global licensing agreement with Kyowa Kirin for its oral selective PI3Kδ inhibitor (ME-401) used for treating B-cell malignancies. More >

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment
Source: Streetwise Reports  (4/10/20)
Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shares traded nearly 17% higher today on the Korean Stock exchange. More >

MediciNova Shares Rise 40% on Plans to Initiate COVID-19 ARDS Clinical Trial
Source: Streetwise Reports  (4/9/20)
Shares of MediciNova traded higher after the company reported that it plans to initiate a clinical study of MN-166 (ibudilast) for COVID-19 acute respiratory distress syndrome. More >

Company Secures Largest Order to Date for Antibiotic-Free Feedstock Supplement
Source: Streetwise Reports  (4/8/20)
Avivagen Inc. has secured its largest ever order of OxC-betaâ„¢ Livestock from its long-standing Philippine partner UNAHCO. More >

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment
Source: Streetwise Reports  (4/8/20)
How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. More >

Novavax Announces Its First-in-Human Coronavirus Vaccine Trial Will Begin in Mid-May
Source: Streetwise Reports  (4/8/20)
Shares of Novavax traded 20% higher setting a new 52-week high price after the company reported that it has accelerated initiation of a Phase 1 clinical trial for its coronavirus vaccine candidate NVX-CoV2373. The study will commence in mid-May with preliminary results expected in July 2020. More >

Immunomedics Shares Double as Phase 3 Breast Cancer Trial Achieves 'Compelling' Efficacy Data
Source: Streetwise Reports  (4/6/20)
Shares of Immunomedics opened 117% higher after the company reported that it has stopped its Phase 3 ASCENT study of sacituzumab govitecan after recording "compelling evidence of efficacy" in heavily pretreated patients with metastatic triple-negative breast cancer. More >

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy
Source: Streetwise Reports  (4/3/20)
Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. More >

Three COVID-19 Patients Treated with PLX Cells
Source: Streetwise Reports  (4/1/20)
Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. More >

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment
Source: Streetwise Reports  (3/31/20)
Shares of Kiniksa Pharmaceuticals traded higher after the company reported early success in treatment response for mavrilimumab in six patients with severe COVID-19 pneumonia and hyperinflammation. More >

Eton Pharma Shares Climb 20% After Firm Secures US Rights for Pediatric Kidney Disease Drug
Source: Streetwise Reports  (3/27/20)
Shares of Eton Pharmaceuticals traded higher after the company reported that it has acquired U.S. marketing rights to pediatric orphan drug Alkindi® Sprinkle from Diurnal Group Plc. More >

Maker of Antibiotic-Free Animal Supplement Lands First Order from Mexico
Source: Streetwise Reports  (3/26/20)
This new market is a significant one for Avivagen. More >

Coronavirus Propels Telemedicine into the Spotlight
Source: McAlinden Research for Streetwise Reports  (3/26/20)
McAlinden Research Partners takes a look at how telemedicine companies are positioned to profit both during and in the wake of the current pandemic, and offers a couple of options for investors. More >